The application progress of nanomaterials in atherosclerotic cardiovascular disease

doi:10.11958/20251227

Abstract

Abstract:

Atherosclerotic cardiovascular diseases (ASCVD) are chronic progressive diseases characterized by endothelial dysfunction, and their traditional therapies have limitations. In recent years, nanocarrier systems have demonstrated significant advantages in targeted delivery, enhancing drug safety and efficacy, thereby offering new strategies for precise diagnosis and treatment of ASCVD. Nanomaterials, including polymer nanoparticles, lipid nanoparticles, inorganic nanoparticles and bio-inspired nanoparticles, can effectively intervene key pathological processes of ASCVD. They achieve therapeutic effects by regulating macrophage balance, preserving endothelial cell function, maintaining smooth muscle cell contractile phenotype and modulating platelet activity. This review summarizes the application characteristics and research progress of different types of nanomaterials in the prevention and treatment of ASCVD, and provides insights into the challenges and future prospects of this field.

Key words: atherosclerosis, nanotechnology, drug carriers, drug delivery systems, cardiovascular diseases

CLC Number:

R543.3

References 44

[1]	SURMA S, FILIPIAK K J. Inflammation and autoimmunity in atherosclerosis[J]. Reumatologia, 2022, 60(1):1-3. doi:10.5114/reum.2022.113364.
[2]	MURRAY C, GBD 2021 COLLABORATORS. Findings from the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440):2259-2262. doi:10.1016/S0140-6736(24)00769-4.
[3]	SORIA-FLORIDO M T, CASTAÑER O, LASSALE C, et al. Dysfunctional high-density lipoproteins are associated with a greater incidence of acute coronary syndrome in a population at high cardiovascular risk:a nested case-control study[J]. Circulation, 2020, 141(6):444-453. doi:10.1161/CIRCULATIONAHA.119.041658.
[4]	FRĄK W, WOJTASIŃSKA A, LISIŃSKA W, et al. Pathophysiology of cardiovascular diseases:new insights into molecular mechanisms of atherosclerosis, arterial hypertension, and coronary artery disease[J]. Biomedicines, 2022, 10(8):1938. doi:10.3390/biomedicines10081938.
[5]	ZHU N, GUO Z F, KAZAMA K, et al. Epigenetic regulation of vascular smooth muscle cell phenotypic switch and neointimal formation by PRMT5[J]. Cardiovasc Res, 2023, 119(12):2244-2255. doi:10.1093/cvr/cvad110.
[6]	RIDKER P M, MOORTHY M V, COOK N R, et al. Inflammation,cholesterol,lipoprotein(a),and 30-year cardiovascular outcomes in women[J]. N Engl J Med, 2024, 391(22):2087-2097. doi:10.1056/NEJMoa2405182.
[7]	NAKAMURA M, SADOSHIMA J. Mechanisms of physiological and pathological cardiac hypertrophy[J]. Nat Rev Cardiol, 2018, 15(7):387-407. doi:10.1038/s41569-018-0007-y.
[8]	WEBER B N, GILES J T, LIAO K P. Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease[J]. Nat Rev Rheumatol, 2023, 19(7):417-428. doi:10.1038/s41584-023-00969-7.
[9]	HUANG X, SONG J, ZHANG X, et al. Understanding drug interactions in antiplatelet therapy for atherosclerotic vascular disease:a systematic review[J]. CNS Neurosci Ther, 2025, 31(2):e70258. doi:10.1111/cns.70258.
[10]	GAWAZ M, GEISLER T, BORST O. Current concepts and novel targets for antiplatelet therapy[J]. Nat Rev Cardiol, 2023, 20(9):583-599. doi:10.1038/s41569-023-00854-6.
[11]	SURMA S, SAHEBKAR A, BANACH M. Coffee or tea:Anti-inflammatory properties in the context of atherosclerotic cardiovascular disease prevention[J]. Pharmacol Res, 2023, 187:106596. doi:10.1016/j.phrs.2022.106596.
[12]	BARUNGI S, HERNÁNDEZ-CAMARERO P, MORENO-TERRIBAS G, et al. Clinical implications of inflammation in atheroma formation and novel therapies in cardiovascular diseases[J]. Front Cell Dev Biol, 2023, 11:1148768. doi:10.3389/fcell.2023.1148768.
[13]	ISSELBACHER E M, PREVENTZA O, HAMILTON BLACK J 3rd, et al. 2022 ACC/AHA Guideline for the diagnosis and management of aortic disease: a report of the american heart association/American college of cardiology joint committee on clinical practice guidelines[J]. Circulation, 2022, 146(24):e334-e482. doi:10.1161/CIR.0000000000001106.
[14]	NI Z, YU H, WANG L, et al. Recent research progress on polyphosphazene-based drug delivery systems[J]. J Mater Chem B, 2020, 8(8):1555-1575. doi:10.1039/c9tb02517k.
[15]	MAHJOUBIN-TEHRAN M, KOVANEN P T, XU S, et al. Cyclodextrins:potential therapeutics against atherosclerosis[J]. Pharmacol Ther, 2020, 214:107620. doi:10.1016/j.pharmthera.2020.107620.
[16]	LI S, SUN S, LUO J, et al. Polymer single-chain nanoparticles:shaping solid surfactants[J]. Macromol Rapid Commun, 2024, 45(21):e2400393. doi:10.1002/marc.202400393.
[17]	SARFRAZ M, AFZAL A, YANG T, et al. Development of dual drug loaded nanosized liposomal formulation by a reengineered ethanolic injection method and its pre-clinical pharmacokinetic studies[J]. Pharmaceutics, 2018, 10(3):151. doi:10.3390/pharmaceutics10030151.
[18]	CHANG C Y, HUANG S H, CHEN C Y, et al. Monocyte-adhesive peptidyl liposomes for harnessing monocyte homing to tumor tissues[J]. J Control Release, 2025, 382:113672. doi:10.1016/j.jconrel.2025.113672.
[19]	YU S, XIA G, YANG N, et al. Noble metal nanoparticle-based photothermal therapy:development and application in effective cancer therapy[J]. Int J Mol Sci, 2024, 25(11):5632. doi:10.3390/ijms25115632.
[20]	DOCKERY L T, DANIEL M C. Targeted doxorubicin-loaded dendronized gold nanoparticles[J]. Pharmaceutics, 2023, 15(8):2103. doi:10.3390/pharmaceutics15082103.
[21]	IMRAISH A, THIAB T A, ZIHLIF M, et al. Anti-inflammatory and antioxidant potential of green synthesized iron zinc oxide(Fe0.25-ZnO)nanoparticles of the elaeagnus angustifolia[J]. Chem Biodivers, 2024, 21(9):e202401060. doi:10.1002/cbdv.202401060.
[22]	YANG L, ZANG G, LI J, et al. Cell-derived biomimetic nanoparticles as a novel drug delivery system for atherosclerosis: predecessors and perspectives[J]. Regen Biomater, 2020, 7(4):349-358. doi:10.1093/rb/rbaa019.
[23]	CHEN J, ZHANG X, MILLICAN R, et al. Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis[J]. Adv Drug Deliv Rev, 2021, 170:142-199. doi:10.1016/j.addr.2021.01.005.
[24]	PANG L, ZHANG C, QIN J, et al. A novel strategy to achieve effective drug delivery:exploit cells as carrier combined with nanoparticles[J]. Drug Deliv, 2017, 24(1):83-91. doi:10.1080/10717544.2016.1230903.
[25]	WANG Y, ZHANG K, LI T, et al. Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications[J]. Theranostics, 2021, 11(1):164-180. doi:10.7150/thno.47841.
[26]	WANG J, WANG J, ZHONG J, et al. LRG1 promotes atherosclerosis by inducing macrophage M1-like polarization[J]. Proc Natl Acad Sci U S A, 2024, 121(35):e2405845121. doi:10.1073/pnas.2405845121.
[27]	THEOFILIS P, OIKONOMOU E, TSIOUFIS K, et al. The role of macrophages in atherosclerosis:pathophysiologic mechanisms and treatment considerations[J]. Int J Mol Sci, 2023, 24(11):9568. doi:10.3390/ijms24119568.
[28]	KOJIMA Y, VOLKMER J P, MCKENNA K, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis[J]. Nature, 2016, 536(7614):86-90. doi:10.1038/nature18935.
[29]	GHOLAMIN S, MITRA S S, FEROZE A H, et al. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors[J]. Sci Transl Med, 2017, 9(381):eaaf2968. doi:10.1126/scitranslmed.aaf2968.
[30]	CUI Y, YU H, BU Z, et al. Focus on the role of the NLRP3 inflammasome in multiple sclerosis:pathogenesis,diagnosis,and therapeutics[J]. Front Mol Neurosci, 2022, 15:894298. doi:10.3389/fnmol.2022.894298.
[31]	LUO Q, DAI L, LI J, et al. Intracellular and extracellular synergistic therapy for restoring macrophage functions via anti-CD47 antibody-conjugated bifunctional nanoparticles in atherosclerosis[J]. Bioact Mater, 2024, 34:326-337. doi:10.1016/j.bioactmat.2023.12.024.
[32]	WU Z, ZHOU M, TANG X, et al. Carrier-free trehalose-based nanomotors targeting macrophages in inflammatory plaque for treatment of atherosclerosis[J]. ACS Nano, 2022, 16(3):3808-3820. doi:10.1021/acsnano.1c08391.
[33]	ZHU L, ZHONG Y, YAN M, et al. Macrophage membrane-encapsulated dopamine-modified poly cyclodextrin multifunctional biomimetic nanoparticles for atherosclerosis therapy[J]. ACS Appl Mater Interfaces, 2024, 16(25):32027-32044. doi:10.1021/acsami.4c04431.
[34]	LIU D, YANG A, LI Y, et al. Targeted delivery of rosuvastatin enhances treatment of hyperhomocysteinemia-induced atherosclerosis using macrophage membrane-coated nanoparticles[J]. J Pharm Anal, 2024, 14(9):100937. doi:10.1016/j.jpha.2024.01.005.
[35]	LIBBY P, HANSSON G K. From focal lipid storage to systemic inflammation:JACC review topic of the week[J]. J Am Coll Cardiol, 2019, 74(12):1594-1607. doi:10.1016/j.jacc.2019.07.061.
[36]	WANG S, WANG Y, LAI X, et al. Minimalist nanocomplex with dual regulation of endothelial function and inflammation for targeted therapy of inflammatory vascular diseases[J]. ACS Nano, 2023, 17(3):2761-2781. doi:10.1021/acsnano.2c11058.
[37]	LIU J, YU X, BRAUCHT A, et al. N-cadherin targeted melanin nanoparticles reverse the endothelial-mesenchymal transition in vascular endothelial cells to potentially slow the progression of atherosclerosis and cancer[J]. ACS Nano, 2024, 18(11):8229-8247. doi:10.1021/acsnano.3c12281.
[38]	DURHAM A L, SPEER M Y, SCATENA M, et al. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness[J]. Cardiovasc Res, 2018, 114(4):590-600. doi:10.1093/cvr/cvy010.
[39]	CHIN D D, POON C, WANG J, et al. miR-145 micelles mitigate atherosclerosis by modulating vascular smooth muscle cell phenotype[J]. Biomaterials, 2021, 273:120810. doi:10.1016/j.biomaterials.2021.120810.
[40]	YU J, MA Y, ZHANG X, et al. β-cyclodextrin and hyaluronic acid-modified targeted nanodelivery system for atherosclerosis prevention[J]. ACS Appl Mater Interfaces, 2024, 16(27):35421-35437. doi:10.1021/acsami.4c01540.
[41]	HUILCAMAN R, VENTURINI W, FUENZALIDA L, et al. Platelets,a key cell in inflammation and atherosclerosis progression[J]. Cells, 2022, 11(6):1014. doi:10.3390/cells11061014.
[42]	COENEN D M, HEINZMANN A, KAREL M, et al. The multifaceted contribution of platelets in the emergence and aftermath of acute cardiovascular events[J]. Atherosclerosis, 2021, 319:132-141. doi:10.1016/j.atherosclerosis.2020.12.017.
[43]	FONTANA F, MOLINARO G, MORONI S, et al. Biomimetic platelet-cloaked nanoparticles for the delivery of anti-inflammatory curcumin in the treatment of atherosclerosis[J]. Adv Healthc Mater, 2024, 13(15):e2302074. doi:10.1002/adhm.202302074.
[44]	CHAI Y, SHANGGUAN L, YU H, et al. Near infrared light-activatable platelet-mimicking NIR-Ⅱ NO nano-prodrug for precise atherosclerosis theranostics[J]. Adv Sci(Weinh), 2024, 11(3):e2304994. doi:10.1002/advs.202304994.